首页 > 最新文献

Indian Journal of Medical Research最新文献

英文 中文
Outcome of individuals with alcoholic cirrhosis hospitalized with first decompensation and their predictors. 首次失代偿住院的酒精性肝硬化患者的预后及其预测因素。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_1690_22
Suprabhat Giri, Sushrut Ingawale, Sidharth Harindanath, Mohit Jain, Pranav Garg, Harish Darak, Sanjay Kumar, Aditya Kale, Akash Shukla

Background objectives: Alcohol is one of most common aetiologies of cirrhosis and decompensated cirrhosis is linked to higher morbidity and death rates. This study looked at the outcomes and mortality associated risk variables of individuals with alcoholic cirrhosis who had hospitalization with their first episode of decompensation.

Methods: Individuals with alcoholic cirrhosis who were hospitalized with the first episode of decompensation [acute decompensation (AD) or acute-on-chronic liver failure (ACLF)] were included in the study and were prospectively followed up until death or 90 days, whichever was earlier.

Results: Of the 227 study participants analyzed, 167 (73.56%) and 60 (26.43%) participants presented as AD and ACLF, respectively. In the ACLF group, the mortality rate at 90 days was higher than in the AD group (48.3 vs 32.3%, P=0.02). In the AD group, participants who initially presented with ascites as opposed to variceal haemorrhage had a greater mortality rate at 90 days (36.4 vs 17.1%, P=0.041). The chronic liver failure-consortium AD score and the lactate-free Asian Pacific Association for the study of the Liver-ACLF research consortium score best-predicted mortality in individuals with AD and ACLF.

Interpretation conclusions: There is significant heterogeneity in the type of decompensation in individuals with alcoholic cirrhosis. We observed significantly high mortality rate among alcoholic participants hospitalized with initial decompensation; deaths occurring in more than one-third of study participants within 90 days.

背景目标:酒精是肝硬化最常见的病因之一,失代偿性肝硬化与较高的发病率和死亡率有关。本研究调查了首次失代偿住院的酒精性肝硬化患者的预后和死亡率相关风险变量:研究纳入了因首次失代偿(急性失代偿(AD)或急性慢性肝衰竭(ACLF))而住院的酒精性肝硬化患者,并对其进行了前瞻性随访,直至死亡或 90 天(以较早者为准):在分析的 227 名研究参与者中,分别有 167 人(73.56%)和 60 人(26.43%)表现为 AD 和 ACLF。在 ACLF 组中,90 天的死亡率高于 AD 组(48.3% 对 32.3%,P=0.02)。在 AD 组中,最初出现腹水而非静脉曲张出血的参与者在 90 天后的死亡率更高(36.4 对 17.1%,P=0.041)。慢性肝衰竭研究联盟的AD评分和无乳酸盐亚太肝病研究协会-ACLF研究联盟评分最能预测AD和ACLF患者的死亡率:酒精性肝硬化患者的失代偿类型存在明显的异质性。我们观察到,因初始失代偿而住院的酒精性参与者死亡率明显较高;超过三分之一的研究参与者在 90 天内死亡。
{"title":"Outcome of individuals with alcoholic cirrhosis hospitalized with first decompensation and their predictors.","authors":"Suprabhat Giri, Sushrut Ingawale, Sidharth Harindanath, Mohit Jain, Pranav Garg, Harish Darak, Sanjay Kumar, Aditya Kale, Akash Shukla","doi":"10.4103/ijmr.ijmr_1690_22","DOIUrl":"https://doi.org/10.4103/ijmr.ijmr_1690_22","url":null,"abstract":"<p><strong>Background objectives: </strong>Alcohol is one of most common aetiologies of cirrhosis and decompensated cirrhosis is linked to higher morbidity and death rates. This study looked at the outcomes and mortality associated risk variables of individuals with alcoholic cirrhosis who had hospitalization with their first episode of decompensation.</p><p><strong>Methods: </strong>Individuals with alcoholic cirrhosis who were hospitalized with the first episode of decompensation [acute decompensation (AD) or acute-on-chronic liver failure (ACLF)] were included in the study and were prospectively followed up until death or 90 days, whichever was earlier.</p><p><strong>Results: </strong>Of the 227 study participants analyzed, 167 (73.56%) and 60 (26.43%) participants presented as AD and ACLF, respectively. In the ACLF group, the mortality rate at 90 days was higher than in the AD group (48.3 vs 32.3%, P=0.02). In the AD group, participants who initially presented with ascites as opposed to variceal haemorrhage had a greater mortality rate at 90 days (36.4 vs 17.1%, P=0.041). The chronic liver failure-consortium AD score and the lactate-free Asian Pacific Association for the study of the Liver-ACLF research consortium score best-predicted mortality in individuals with AD and ACLF.</p><p><strong>Interpretation conclusions: </strong>There is significant heterogeneity in the type of decompensation in individuals with alcoholic cirrhosis. We observed significantly high mortality rate among alcoholic participants hospitalized with initial decompensation; deaths occurring in more than one-third of study participants within 90 days.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of molecular diagnostic test for detection of adult pulmonary tuberculosis: A generic protocol. 评估用于检测成人肺结核的分子诊断测试:通用方案。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2316_23
Madhumathi Jayaprakasam, Ravindra Mohan Pandey, Hansraj Choudhary, Sivakumar Shanmugam, Gomathi N Sivaramakrishnan, Nivedita Gupta

Background objectives: Tuberculosis (TB) continues to be the second most-leading cause of death due to a single infectious agent as of 2022 after COVID-19. Many affordable new molecular diagnostic tools are being developed for early and more accurate diagnosis, especially for low-resource settings in low- and middle-income countries. In this context, there is a need to develop a standardized protocol for validation of new diagnostic tools. Here, we describe a generic protocol for multi-centric clinical evaluation of molecular diagnostic tests for adult pulmonary TB.

Methods: This protocol describes a cross-sectional study in TB reference laboratories in India. Adults (>18 yr) visitng the chest clinics or outpatient departments with symptoms of TB need to be enrolled consecutively till the required sample size of 150 culture positives and 470 culture negatives are met. Mycobacterium tuberculosis (Mtb) culture (mycobacteria growth indicator tube liquid culture) to be used under this protocol as the gold standard and Xpert MTB/RIF molecular test will be used as the comparator. The sputum samples will be tested by smear microscopy, Mtb culture, Xpert MTB/RIF and index molecular test as per the proposed algorithm. The specificity sensitivity, and positive/ negative predictive values are to be calculated for the index test with reference to the gold standard.

Discussion: TB diagnosis poses many challenges as it differs with type of disease, age group, clinical settings and type of diagnostic tests/kits used. Globally, different protocols are used by several investigators. This protocol provides standard methods for the validation of molecular tests for diagnosis of adult pulmonary TB, which can be adopted by investigators.

背景目标:截至 2022 年,结核病(TB)仍是仅次于 COVID-19 的第二大单一传染病致死病因。目前正在开发许多经济实惠的新型分子诊断工具,用于早期和更准确的诊断,特别是针对中低收入国家的低资源环境。在这种情况下,有必要为新诊断工具的验证制定标准化方案。在此,我们介绍一种通用方案,用于对成人肺结核分子诊断测试进行多中心临床评估:本方案描述了在印度结核病参考实验室进行的一项横断面研究。根据本方案,结核分枝杆菌(Mtb)培养(分枝杆菌生长指示管液体培养)将作为金标准,Xpert MTB/RIF 分子检测将作为比较标准。根据建议的算法,痰样本将通过涂片显微镜、Mtb 培养、Xpert MTB/RIF 和指标分子检测进行检测。将参照金标准计算指标检测的特异性、敏感性和阳性/阴性预测值:结核病诊断因疾病类型、年龄组、临床环境和所用诊断检测/工具包类型的不同而面临诸多挑战。在全球范围内,一些研究者使用不同的方案。本方案为成人肺结核诊断分子检验的验证提供了标准方法,可供研究人员采用。
{"title":"Evaluation of molecular diagnostic test for detection of adult pulmonary tuberculosis: A generic protocol.","authors":"Madhumathi Jayaprakasam, Ravindra Mohan Pandey, Hansraj Choudhary, Sivakumar Shanmugam, Gomathi N Sivaramakrishnan, Nivedita Gupta","doi":"10.4103/ijmr.ijmr_2316_23","DOIUrl":"10.4103/ijmr.ijmr_2316_23","url":null,"abstract":"<p><strong>Background objectives: </strong>Tuberculosis (TB) continues to be the second most-leading cause of death due to a single infectious agent as of 2022 after COVID-19. Many affordable new molecular diagnostic tools are being developed for early and more accurate diagnosis, especially for low-resource settings in low- and middle-income countries. In this context, there is a need to develop a standardized protocol for validation of new diagnostic tools. Here, we describe a generic protocol for multi-centric clinical evaluation of molecular diagnostic tests for adult pulmonary TB.</p><p><strong>Methods: </strong>This protocol describes a cross-sectional study in TB reference laboratories in India. Adults (>18 yr) visitng the chest clinics or outpatient departments with symptoms of TB need to be enrolled consecutively till the required sample size of 150 culture positives and 470 culture negatives are met. Mycobacterium tuberculosis (Mtb) culture (mycobacteria growth indicator tube liquid culture) to be used under this protocol as the gold standard and Xpert MTB/RIF molecular test will be used as the comparator. The sputum samples will be tested by smear microscopy, Mtb culture, Xpert MTB/RIF and index molecular test as per the proposed algorithm. The specificity sensitivity, and positive/ negative predictive values are to be calculated for the index test with reference to the gold standard.</p><p><strong>Discussion: </strong>TB diagnosis poses many challenges as it differs with type of disease, age group, clinical settings and type of diagnostic tests/kits used. Globally, different protocols are used by several investigators. This protocol provides standard methods for the validation of molecular tests for diagnosis of adult pulmonary TB, which can be adopted by investigators.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of prescriptions from tertiary care hospitals across India for deviations from treatment guidelines & their potential consequences. 评估印度三级医院的处方是否偏离治疗指南及其潜在后果。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2309_22
Yashashri Shetty, Sandhya Kamat, Raakhi Tripathi, Urwashi Parmar, Ratinder Jhaj, Aditya Banerjee, Sadasivam Balakrishnan, Niyati Trivedi, Janki Chauhan, Preeta Kaur Chugh, C D Tripathi, Dinesh Kumar Badyal, Lydia Solomon, Sandeep Kaushal, Kanchan Gupta, M Jayanthi, G Jeevitha, Suparna Chatterjee, Kalyan Samanta, Chetna Desai, Samidh Shah, Bikash Medhi, Rupa Joshi, Ajay Prakash, Pooja Gupta, Atanu Roy, Sujith Chandy, Jaya Ranjalkar, Heber Rew Bright, Harihar Dikshit, Hitesh Mishra, Sukalyan Saha Roy, Nilima Kshirsagar

Background objectives: Irrational prescribing practices have major consequences on patient safety and also increase the economic burden. Real-life examples of impact of irrational prescription have potential to improve prescribing practices. In this context, the present study aimed to capture and evaluate the prevalence of deviations from treatment guidelines in the prescriptions, potential consequence/s of the deviations and corrective actions recommended by clinicians.

Methods: It was a cross-sectional observational study conducted in the outpatient departments of tertiary care hospitals in India wherein the 13 Indian Council of Medical Research Rational Use of Medicines Centres are located. Prescriptions not compliant with the standard treatment guidelines and incomplete prescriptions with respect to formulation, dose, duration and frequency were labelled as 'prescriptions having deviations'. A deviation that could result in a drug interaction, lack of response, increased cost, preventable adverse drug reaction (ADR) and/or antimicrobial resistance was labelled as an 'unacceptable deviation'.

Results: Against all the prescriptions assessed, about one tenth of them (475/4838; 9.8%) had unacceptable deviations. However, in 2667/4838 (55.1%) prescriptions, the clinicians had adhered to the treatment guidelines. Two thousand one hundred and seventy-one prescriptions had deviations, of which 475 (21.9%) had unacceptable deviations with pantoprazole (n=54), rabeprazole+domperidone (n=35) and oral enzyme preparations (n=24) as the most frequently prescribed drugs and upper respiratory tract infection (URTI) and hypertension as most common diseases with unacceptable deviations. The potential consequences of deviations were increase in cost (n=301), ADRs (n=254), drug interactions (n=81), lack of therapeutic response (n=77) and antimicrobial resistance (n=72). Major corrective actions proposed for consideration were issuance of an administrative order (n=196) and conducting online training programme (n=108).

Interpretation conclusions: The overall prevalence of deviations found was 45 per cent of which unacceptable deviations was estimated to be 9.8 per cent. To minimize the deviations, clinicians recommended online training on rational prescribing and administrative directives as potential interventions.

背景目标:不合理处方会对患者安全造成重大影响,同时也会增加经济负担。不合理处方影响的真实案例有可能改善处方实践。在此背景下,本研究旨在了解和评估处方偏离治疗指南的普遍程度、偏离的潜在后果以及临床医生建议采取的纠正措施:这是一项横断面观察研究,在印度 13 家印度医学研究理事会合理用药中心所在的三级医院门诊部进行。不符合标准治疗指南的处方以及配方、剂量、持续时间和频率不完整的处方被称为 "有偏差的处方"。可能导致药物相互作用、缺乏反应、成本增加、可预防的药物不良反应和/或抗菌药耐药性的偏差被称为 "不可接受的偏差":在所有接受评估的处方中,约有十分之一(475/4838;9.8%)存在不可接受的偏差。然而,在 2667/4838 张(55.1%)处方中,临床医生都遵守了治疗指南。2 171 份处方存在偏差,其中 475 份(21.9%)存在不可接受的偏差,泮托拉唑(54 份)、雷贝拉唑+多潘立酮(35 份)和口服酶制剂(24 份)是最常处方的药物,上呼吸道感染(URTI)和高血压是存在不可接受偏差的最常见疾病。偏差的潜在后果包括费用增加(301 人)、不良反应(254 人)、药物相互作用(81 人)、缺乏治疗反应(77 人)和抗菌药耐药性(72 人)。建议考虑采取的主要纠正措施是发布行政命令(196 人)和开展在线培训计划(108 人):发现的总体偏差率为 45%,其中不可接受的偏差率估计为 9.8%。为尽量减少偏差,临床医生建议将合理处方在线培训和行政指令作为潜在的干预措施。
{"title":"Evaluation of prescriptions from tertiary care hospitals across India for deviations from treatment guidelines & their potential consequences.","authors":"Yashashri Shetty, Sandhya Kamat, Raakhi Tripathi, Urwashi Parmar, Ratinder Jhaj, Aditya Banerjee, Sadasivam Balakrishnan, Niyati Trivedi, Janki Chauhan, Preeta Kaur Chugh, C D Tripathi, Dinesh Kumar Badyal, Lydia Solomon, Sandeep Kaushal, Kanchan Gupta, M Jayanthi, G Jeevitha, Suparna Chatterjee, Kalyan Samanta, Chetna Desai, Samidh Shah, Bikash Medhi, Rupa Joshi, Ajay Prakash, Pooja Gupta, Atanu Roy, Sujith Chandy, Jaya Ranjalkar, Heber Rew Bright, Harihar Dikshit, Hitesh Mishra, Sukalyan Saha Roy, Nilima Kshirsagar","doi":"10.4103/ijmr.ijmr_2309_22","DOIUrl":"10.4103/ijmr.ijmr_2309_22","url":null,"abstract":"<p><strong>Background objectives: </strong>Irrational prescribing practices have major consequences on patient safety and also increase the economic burden. Real-life examples of impact of irrational prescription have potential to improve prescribing practices. In this context, the present study aimed to capture and evaluate the prevalence of deviations from treatment guidelines in the prescriptions, potential consequence/s of the deviations and corrective actions recommended by clinicians.</p><p><strong>Methods: </strong>It was a cross-sectional observational study conducted in the outpatient departments of tertiary care hospitals in India wherein the 13 Indian Council of Medical Research Rational Use of Medicines Centres are located. Prescriptions not compliant with the standard treatment guidelines and incomplete prescriptions with respect to formulation, dose, duration and frequency were labelled as 'prescriptions having deviations'. A deviation that could result in a drug interaction, lack of response, increased cost, preventable adverse drug reaction (ADR) and/or antimicrobial resistance was labelled as an 'unacceptable deviation'.</p><p><strong>Results: </strong>Against all the prescriptions assessed, about one tenth of them (475/4838; 9.8%) had unacceptable deviations. However, in 2667/4838 (55.1%) prescriptions, the clinicians had adhered to the treatment guidelines. Two thousand one hundred and seventy-one prescriptions had deviations, of which 475 (21.9%) had unacceptable deviations with pantoprazole (n=54), rabeprazole+domperidone (n=35) and oral enzyme preparations (n=24) as the most frequently prescribed drugs and upper respiratory tract infection (URTI) and hypertension as most common diseases with unacceptable deviations. The potential consequences of deviations were increase in cost (n=301), ADRs (n=254), drug interactions (n=81), lack of therapeutic response (n=77) and antimicrobial resistance (n=72). Major corrective actions proposed for consideration were issuance of an administrative order (n=196) and conducting online training programme (n=108).</p><p><strong>Interpretation conclusions: </strong>The overall prevalence of deviations found was 45 per cent of which unacceptable deviations was estimated to be 9.8 per cent. To minimize the deviations, clinicians recommended online training on rational prescribing and administrative directives as potential interventions.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140287304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does Lake Louise questionnaire interpret high-altitude headache as acute mountain sickness? Experience in the western Himalayas. 路易斯湖调查问卷是否将高海拔头痛解释为急性高山病?喜马拉雅山西部的经验。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2127_21
Abhilash Unnikrishnan, Atul Shekhar, Dharmendra Kumar, Raksha Jaipurkar, Gaurav Sikri, Krishan Singh, Rahul Manral

Background objectives: High-altitude headache (HAH) and headache in acute mountain sickness (AMS) are common among lowlanders ascending to the high altitude and are often confused with one another. A pilot study was undertaken to analyze HAH and AMS cases in Indian lowlanders ascending to Leh city (3500 m) in western Himalayas.

Methods: A total number of 1228 Indian lowlanders, who ascended (fresh and re-inductees) by air and acclimatized, participated in this pilot study. The intensity of headache was assessed by the Visual Analogue Score. The parameters of HAH as per the International Classification of Headache Disorders-3 and 2018 Revised Lake Louise Questionnaire (LLQ) were used to differentiate HAH and AMS.

Results: Out of 1228 cases, 78 (6.4%) cases had headache, of which 24 (1.95%) cases were HAH only, 40 (3.25%) cases AMS only and 14 (1.14%) cases were defined as both HAH and AMS. There was a significant difference in heart rate [F (2,51) = (4.756), P =0.01] between these groups. It also showed a difference in the correlation between the parameters within the groups. The Odd's Ratio of AMS in fresh and re-inductees was found to be 4.5 and for HAH it was 4.33.

Interpretation conclusions: The findings of this study suggest that LLQ has a tendency of overestimating AMS by including HAH cases. Furthermore differential parameters exhibit differences when AMS and HAH are considered separately. Re-inductees showed a lower incidence of HAH and AMS.

背景目标:高海拔头痛(HAH)和急性高山症头痛(AMS)是低地人前往高海拔地区的常见病,两者经常被混淆。我们开展了一项试验性研究,分析印度低地居民前往喜马拉雅山西部雷城(海拔 3500 米)的高海拔头痛和急性高山症病例:共有 1228 名印度低地人参加了这项试点研究,他们都是乘飞机登山(新登山者和再次登山者)并适应了当地气候。头痛的强度通过视觉模拟评分进行评估。根据《国际头痛疾病分类-3》和 2018 年修订的路易斯湖问卷(LLQ)得出的 HAH 参数用于区分 HAH 和 AMS:在1228例病例中,78例(6.4%)有头痛,其中24例(1.95%)仅为HAH,40例(3.25%)仅为AMS,14例(1.14%)同时被定义为HAH和AMS。这些组别之间的心率存在明显差异[F (2,51) = (4.756),P=0.01]。这也显示了组内参数之间相关性的差异。研究发现,新入选者和重新入选者的 AMS 的奇数比为 4.5,HAH 为 4.33:这项研究的结果表明,LLQ 有可能因为包括了 HAH 病例而高估 AMS。此外,当分别考虑 AMS 和 HAH 时,差异参数也会出现差异。再次入选者的 HAH 和 AMS 发生率较低。
{"title":"Does Lake Louise questionnaire interpret high-altitude headache as acute mountain sickness? Experience in the western Himalayas.","authors":"Abhilash Unnikrishnan, Atul Shekhar, Dharmendra Kumar, Raksha Jaipurkar, Gaurav Sikri, Krishan Singh, Rahul Manral","doi":"10.4103/ijmr.ijmr_2127_21","DOIUrl":"10.4103/ijmr.ijmr_2127_21","url":null,"abstract":"<p><strong>Background objectives: </strong>High-altitude headache (HAH) and headache in acute mountain sickness (AMS) are common among lowlanders ascending to the high altitude and are often confused with one another. A pilot study was undertaken to analyze HAH and AMS cases in Indian lowlanders ascending to Leh city (3500 m) in western Himalayas.</p><p><strong>Methods: </strong>A total number of 1228 Indian lowlanders, who ascended (fresh and re-inductees) by air and acclimatized, participated in this pilot study. The intensity of headache was assessed by the Visual Analogue Score. The parameters of HAH as per the International Classification of Headache Disorders-3 and 2018 Revised Lake Louise Questionnaire (LLQ) were used to differentiate HAH and AMS.</p><p><strong>Results: </strong>Out of 1228 cases, 78 (6.4%) cases had headache, of which 24 (1.95%) cases were HAH only, 40 (3.25%) cases AMS only and 14 (1.14%) cases were defined as both HAH and AMS. There was a significant difference in heart rate [F (2,51) = (4.756), P =0.01] between these groups. It also showed a difference in the correlation between the parameters within the groups. The Odd's Ratio of AMS in fresh and re-inductees was found to be 4.5 and for HAH it was 4.33.</p><p><strong>Interpretation conclusions: </strong>The findings of this study suggest that LLQ has a tendency of overestimating AMS by including HAH cases. Furthermore differential parameters exhibit differences when AMS and HAH are considered separately. Re-inductees showed a lower incidence of HAH and AMS.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152. 对 SARS-CoV-2 Omicron 变体的中和抗体反应:接种两剂和三剂 ChAdOx1 nCoV-19 或 BBV152 疫苗六个月后的反应。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_948_23
Pragya D Yadav, Viren Sardana, Gururaj Rao Deshpande, Pradnya V Shinde, Jeromie Wesley Vivian Thangaraj, Leyanna S George, Gajanan N Sapkal, Deepak Y Patil, Rima R Sahay, Anita M Shete, Madhavi Joshi, Manoj Murhekar, Sheela Godbole, Nivedita Gupta, Satyartha Prakash, Mamta Rathore, Rajat Ujjainiya, Ajay Pratap Singh, Aastha Mishra, Debasis Dash, Kumardeep Chaudhary, Shantanu Sengupta

Background objectives: The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 and March - April 2023, India witnessed increased SARS-CoV-2 infections, mostly due to newer Omicron sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) and BBV152 (Covaxin) against emerging Omicron sub-lineages.

Methods: Neutralizing antibody responses were measured in the sera collected from individuals six months post-two doses (n=88) of Covishield (n=44) or Covaxin (n=44) and post-three doses (n=102) of Covishield (n=46) or Covaxin (n=56) booster dose against prototype B.1 strain, lineages of Omicron; XBB.1, BQ.1, BA.5.2 and BF.7.

Results: The sera of individuals collected six months after the two-dose and the three-dose demonstrated neutralizing activity against all variants. The neutralizing antibody (NAbs) level was highest against the prototype B.1 strain, followed by BA5.2 (5-6 fold lower), BF.7 (11-12 fold lower), BQ.1 (12 fold lower) and XBB.1 (18-22 fold lower).

Interpretation conclusions: Persistence of NAb responses was comparable in individuals with two- and three-dose groups post six months of vaccination. Among the Omicron sub-variants, XBB.1 showed marked neutralization escape, thus pointing towards an eventual immune escape, which may cause more infections. Further, the correlation of study data with complete clinical profile of the participants along with observations for cell-mediated immunity may provide a clear picture for the sustained protection due to three-dose vaccination as well as hybrid immunity against the newer variants.

背景目标:众所周知,Omicron 亚系具有较高的传染性、免疫逃逸能力和较低的毒力。在 2022 年 12 月至 2023 年 1 月以及 2023 年 3 月至 4 月期间,印度的 SARS-CoV-2 感染病例有所增加,主要是由于较新的 Omicron 亚系所致。在病例空前增多的情况下,我们评估了接种 ChAdOx1 nCoV (Covishield) 和 BBV152 (Covaxin) 疫苗的个体对新出现的 Omicron 亚系的中和潜力:方法: 在接种两剂(88 人)Covishield(44 人)或 Covaxin(44 人)后六个月,以及接种三剂(102 人)Covishield(46 人)或 Covaxin(56 人)加强剂后六个月,对个人血清中针对原型 B.1 株、Omicron 亚系 XBB.1、BQ.1、BA.5.2 和 BF.7 的中和抗体反应进行了测定:在注射两剂和三剂后六个月采集的血清显示出对所有变异株的中和活性。针对原型 B.1 株的中和抗体(NAbs)水平最高,其次是 BA5.2(低 5-6 倍)、BF.7(低 11-12 倍)、BQ.1(低 12 倍)和 XBB.1(低 18-22 倍):结论:接种六个月后,两剂组和三剂组的 NAb 反应持续时间相当。在 Omicron 亚变异株中,XBB.1 表现出明显的中和逃逸,这表明最终会出现免疫逃逸,从而导致更多感染。此外,研究数据与参与者完整的临床概况以及细胞介导免疫观察结果之间的相关性可以清楚地说明三剂疫苗接种所带来的持续保护以及针对较新变种的混合免疫。
{"title":"Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.","authors":"Pragya D Yadav, Viren Sardana, Gururaj Rao Deshpande, Pradnya V Shinde, Jeromie Wesley Vivian Thangaraj, Leyanna S George, Gajanan N Sapkal, Deepak Y Patil, Rima R Sahay, Anita M Shete, Madhavi Joshi, Manoj Murhekar, Sheela Godbole, Nivedita Gupta, Satyartha Prakash, Mamta Rathore, Rajat Ujjainiya, Ajay Pratap Singh, Aastha Mishra, Debasis Dash, Kumardeep Chaudhary, Shantanu Sengupta","doi":"10.4103/ijmr.ijmr_948_23","DOIUrl":"10.4103/ijmr.ijmr_948_23","url":null,"abstract":"<p><strong>Background objectives: </strong>The Omicron sub-lineages are known to have higher infectivity, immune escape and lower virulence. During December 2022 - January 2023 and March - April 2023, India witnessed increased SARS-CoV-2 infections, mostly due to newer Omicron sub-lineages. With this unprecedented rise in cases, we assessed the neutralization potential of individuals vaccinated with ChAdOx1 nCoV (Covishield) and BBV152 (Covaxin) against emerging Omicron sub-lineages.</p><p><strong>Methods: </strong>Neutralizing antibody responses were measured in the sera collected from individuals six months post-two doses (n=88) of Covishield (n=44) or Covaxin (n=44) and post-three doses (n=102) of Covishield (n=46) or Covaxin (n=56) booster dose against prototype B.1 strain, lineages of Omicron; XBB.1, BQ.1, BA.5.2 and BF.7.</p><p><strong>Results: </strong>The sera of individuals collected six months after the two-dose and the three-dose demonstrated neutralizing activity against all variants. The neutralizing antibody (NAbs) level was highest against the prototype B.1 strain, followed by BA5.2 (5-6 fold lower), BF.7 (11-12 fold lower), BQ.1 (12 fold lower) and XBB.1 (18-22 fold lower).</p><p><strong>Interpretation conclusions: </strong>Persistence of NAb responses was comparable in individuals with two- and three-dose groups post six months of vaccination. Among the Omicron sub-variants, XBB.1 showed marked neutralization escape, thus pointing towards an eventual immune escape, which may cause more infections. Further, the correlation of study data with complete clinical profile of the participants along with observations for cell-mediated immunity may provide a clear picture for the sustained protection due to three-dose vaccination as well as hybrid immunity against the newer variants.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140184280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular detection of Orientia tsutsugamushi in ectoparasites & their small mammal hosts captured from scrub typhus endemic areas in Madurai district, India. 从印度马杜赖地区恙虫病流行地区捕获的体外寄生虫及其小型哺乳动物宿主体内进行Orientia tsutsugamushi的分子检测。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_3530_21
R Govindarajan, S Gowri Sankar, M Senthil Kumar, V Rajamannar, R Krishnamoorthi, A Alwin Prem Anand, Ashwani Kumar, P Philip Samuel

Background objectives: Scrub typhus, caused by Orientia tsutsugamushi present in small mammals harbouring the ectoparasites. A study was undertaken to detect the pathogen present in small mammals and its ectoparasites in the scrub typhus-reported areas.

Methods: The small mammals (rodents/shrews) and its ectoparasites were screened for O. tsutsugamushi using nested PCR amplification of the groEL gene. Small mammals were collected by trapping and screened for ectoparasites (mites, ticks and fleas) by combing method.

Results: All the chigger mites collected were tested negative for O. tsutsugamushi . Interestingly, adult non-trombiculid mites ( Oribatida sp., Dermanyssus gallinae ), fleas ( Xenopsylla astia, X. cheopis, Ctenophalides felis and Ctenophalides sp.) and ticks ( Rhipicephalus sanguineus , R. haemaphysaloides ) screened were found to be positive for O. tsutsugamushi , which the authors believe is the first report on these species globally. Bandicota bengalensis with O. tsutsugamushi infection is reported for the first time in India. The O. tsutsugamushi groEL sequences from the positive samples were similar to the reference strains, Karp and Ikeda and phylogenetically clustered in clade IV with less evolutionary divergence. The blood samples of Rattus rattus , Suncus murinus and B. bengalensis collected from this area were tested positive for O. tsutsugamushi ; interestingly, the sequence similarity was much pronounced with their ectoparasites indicating the transmission of the pathogen to host or vice versa .

Interpretation conclusions: The outcome of the present investigations widened our scope on the pathogens present in ectoparasites and rodents/shrews from this area. This will help to formulate the required vector control methods to combat zoonotic diseases.

背景目标:恙虫病是由寄生在小型哺乳动物体外的恙虫引起的。我们开展了一项研究,以检测恙虫病报告地区小型哺乳动物及其体外寄生虫中的病原体:方法:利用巢式 PCR 扩增 groEL 基因,对小型哺乳动物(啮齿类动物/鼩鼱)及其体外寄生虫进行恙虫病筛查。用诱捕法收集小型哺乳动物,并用梳理法筛查其体外寄生虫(螨、蜱和跳蚤):结果:收集到的所有恙螨对 O. tsutsugamushi 均呈阴性。有趣的是,筛查出的非蓟马成螨(Oribatida sp.、Dermanyssus gallinae)、跳蚤(Xenopsylla astia、X. cheopis、Ctenophalides felis 和 Ctenophalides sp.)和蜱(Rhipicephalus sanguineus、R. haemaphysaloides)对恙虫螨呈阳性,作者认为这是全球首次报告这些物种。Bandicota bengalensis 感染 O. tsutsugamushi 的报道在印度尚属首次。阳性样本中的O. tsutsugamushi groEL序列与参考菌株Karp和Ikeda相似,在系统发育上聚类于支系IV,进化分歧较小。从这一地区采集的鼠类、鼠类孙鸡(Suncus murinus)和孟加拉鼠(B. bengalensis)的血液样本对O. tsutsugamushi检测呈阳性;有趣的是,与它们的外寄生虫的序列相似性非常明显,这表明病原体可传播给宿主,反之亦然:本次调查的结果扩大了我们对该地区外寄生虫和啮齿动物/鼩鼱体内病原体的研究范围。这将有助于制定防治人畜共患病所需的病媒控制方法。
{"title":"Molecular detection of Orientia tsutsugamushi in ectoparasites & their small mammal hosts captured from scrub typhus endemic areas in Madurai district, India.","authors":"R Govindarajan, S Gowri Sankar, M Senthil Kumar, V Rajamannar, R Krishnamoorthi, A Alwin Prem Anand, Ashwani Kumar, P Philip Samuel","doi":"10.4103/ijmr.ijmr_3530_21","DOIUrl":"10.4103/ijmr.ijmr_3530_21","url":null,"abstract":"<p><strong>Background objectives: </strong>Scrub typhus, caused by Orientia tsutsugamushi present in small mammals harbouring the ectoparasites. A study was undertaken to detect the pathogen present in small mammals and its ectoparasites in the scrub typhus-reported areas.</p><p><strong>Methods: </strong>The small mammals (rodents/shrews) and its ectoparasites were screened for O. tsutsugamushi using nested PCR amplification of the groEL gene. Small mammals were collected by trapping and screened for ectoparasites (mites, ticks and fleas) by combing method.</p><p><strong>Results: </strong>All the chigger mites collected were tested negative for O. tsutsugamushi . Interestingly, adult non-trombiculid mites ( Oribatida sp., Dermanyssus gallinae ), fleas ( Xenopsylla astia, X. cheopis, Ctenophalides felis and Ctenophalides sp.) and ticks ( Rhipicephalus sanguineus , R. haemaphysaloides ) screened were found to be positive for O. tsutsugamushi , which the authors believe is the first report on these species globally. Bandicota bengalensis with O. tsutsugamushi infection is reported for the first time in India. The O. tsutsugamushi groEL sequences from the positive samples were similar to the reference strains, Karp and Ikeda and phylogenetically clustered in clade IV with less evolutionary divergence. The blood samples of Rattus rattus , Suncus murinus and B. bengalensis collected from this area were tested positive for O. tsutsugamushi ; interestingly, the sequence similarity was much pronounced with their ectoparasites indicating the transmission of the pathogen to host or vice versa .</p><p><strong>Interpretation conclusions: </strong>The outcome of the present investigations widened our scope on the pathogens present in ectoparasites and rodents/shrews from this area. This will help to formulate the required vector control methods to combat zoonotic diseases.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary lipoarabinomannan in individuals with sputum-negative pulmonary tuberculosis. 痰液阴性肺结核患者尿液中的脂联素甘露聚糖。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2074_22
P Ajantha, Man Mohan Puri, Devika Tayal, U Khalid

Background objectives: Tuberculosis (TB) is a major global cause of ill health. Sputum microscopy for confirmation of presumptive pulmonary TB (PTB) has a reportedly low sensitivity of 22-43 per cent for single smear and up to 60 per cent under optimal conditions. National TB Elimination Programme in India recommends the use of cartridge-based nucleic acid amplification test (CBNAAT) and culture for microbiological confirmation in presumptive PTB individuals with sputum smear negative test. The use of lateral flow urine lipoarabinomannan (LF-LAM) is usually recommended for the diagnosis of TB in HIV-positive individuals with low CD4 counts or those who are seriously ill. The objective of this study was to detect urinary LAM using cage nanotechnology that does not require a physiologic or immunologic consequence of HIV infection for LAM quantification in human urine in 50 HIV-seronegative sputum smear-negative PTB individuals.

Methods: To study the diagnostic value of urinary LAM in sputum smear negative PTB individuals, a cage based nanotechnology ELISA technique was used for urinary LAM in three different groups of participants. Fifty smears negative PTB clinically diagnosed, 15 smear positive PTB and 15 post TB sequel individuals. Sputum was tested by smear, CBNAAT, and culture along with urine LAM before treatment. The results were interpreted by ROC curve in comparison to the standard tests like CBNAAT and culture.

Results: The mean urinary LAM value was 0.84 ng/ml in 37 culture-positive [Mycobacterium tuberculosis (M.tb)] and 0.49 ng/ml in 13 culture-negative (M.tb) smear-negative individuals with PTB, respectively. In 47 smear-negative PTB cases with microbiologically confirmed TB by CBNAAT, the mean urinary LAM was 0.76 ng/ml. The mean urinary LAM in post-TB sequel individuals was 0.47 ng/ml. As per the receiver operating characteristic curve, cut-off value of urinary LAM in individuals with smear-negative PTB microbiologically confirmed by: (i) CBNAAT was 0.695 ng/ml and (ii) culture was 0.615 ng/ml.

Interpretation conclusions: The findings of this study suggest that individuals with smear-negative PTB and a urinary LAM value of >0.615 ng/ml were most likely to have microbiological confirmed TB while those with a LAM value <0.615 ng/ml >0.478 ng/ml are less likely and those with a value <0.478 ng/ml are unlikely to have microbiological confirmed TB.

背景目标:结核病(TB)是全球健康不良的主要原因。据报道,用痰显微镜确认推定肺结核(PTB)的灵敏度较低,单次涂片灵敏度为 22%-43%,在最佳条件下可高达 60%。印度国家消除结核病计划建议对痰涂片检测阴性的推定肺结核患者使用盒式核酸扩增检测(CBNAAT)和培养进行微生物确认。通常建议使用侧流尿液脂联素(LF-LAM)来诊断 CD4 细胞数较低的 HIV 阳性者或重症患者的结核病。本研究的目的是利用笼式纳米技术检测尿液中的 LAM,该技术无需 HIV 感染的生理或免疫后果,即可对 50 名 HIV 阴性痰涂片阴性 PTB 患者尿液中的 LAM 进行定量:为了研究痰涂片阴性 PTB 患者尿液中 LAM 的诊断价值,在三组不同的参与者中使用了基于笼子的纳米技术 ELISA 技术检测尿液中的 LAM。其中包括 50 名临床诊断为涂片阴性的 PTB 患者、15 名涂片阳性的 PTB 患者和 15 名结核病后遗症患者。治疗前对痰液进行涂片、CBNAAT、培养和尿液 LAM 检测。结果通过 ROC 曲线与 CBNAAT 和培养等标准检测进行比较:结果:在 37 名培养阳性(结核分枝杆菌(M.tb))和 13 名培养阴性(M.tb)涂片阴性的 PTB 患者中,尿液 LAM 平均值分别为 0.84 纳克/毫升和 0.49 纳克/毫升。在 47 例经 CBNAAT 微生物学确诊的涂片阴性 PTB 患者中,尿液 LAM 平均值为 0.76 纳克/毫升。结核病后遗症患者的尿液 LAM 平均值为 0.47 纳克/毫升。根据接收器操作特征曲线,经涂片阴性、微生物学确诊的肺结核患者的尿液 LAM 临界值为(解释性结论:本研究结果表明,涂片阴性 PTB 患者的尿液 LAM 值大于 0.615 ng/ml,最有可能经微生物学确诊为肺结核,而 LAM 值为 0.478 ng/ml 的患者的可能性较低,LAM 值为 0.615 ng/ml 的患者的可能性较高。
{"title":"Urinary lipoarabinomannan in individuals with sputum-negative pulmonary tuberculosis.","authors":"P Ajantha, Man Mohan Puri, Devika Tayal, U Khalid","doi":"10.4103/ijmr.ijmr_2074_22","DOIUrl":"https://doi.org/10.4103/ijmr.ijmr_2074_22","url":null,"abstract":"<p><strong>Background objectives: </strong>Tuberculosis (TB) is a major global cause of ill health. Sputum microscopy for confirmation of presumptive pulmonary TB (PTB) has a reportedly low sensitivity of 22-43 per cent for single smear and up to 60 per cent under optimal conditions. National TB Elimination Programme in India recommends the use of cartridge-based nucleic acid amplification test (CBNAAT) and culture for microbiological confirmation in presumptive PTB individuals with sputum smear negative test. The use of lateral flow urine lipoarabinomannan (LF-LAM) is usually recommended for the diagnosis of TB in HIV-positive individuals with low CD4 counts or those who are seriously ill. The objective of this study was to detect urinary LAM using cage nanotechnology that does not require a physiologic or immunologic consequence of HIV infection for LAM quantification in human urine in 50 HIV-seronegative sputum smear-negative PTB individuals.</p><p><strong>Methods: </strong>To study the diagnostic value of urinary LAM in sputum smear negative PTB individuals, a cage based nanotechnology ELISA technique was used for urinary LAM in three different groups of participants. Fifty smears negative PTB clinically diagnosed, 15 smear positive PTB and 15 post TB sequel individuals. Sputum was tested by smear, CBNAAT, and culture along with urine LAM before treatment. The results were interpreted by ROC curve in comparison to the standard tests like CBNAAT and culture.</p><p><strong>Results: </strong>The mean urinary LAM value was 0.84 ng/ml in 37 culture-positive [Mycobacterium tuberculosis (M.tb)] and 0.49 ng/ml in 13 culture-negative (M.tb) smear-negative individuals with PTB, respectively. In 47 smear-negative PTB cases with microbiologically confirmed TB by CBNAAT, the mean urinary LAM was 0.76 ng/ml. The mean urinary LAM in post-TB sequel individuals was 0.47 ng/ml. As per the receiver operating characteristic curve, cut-off value of urinary LAM in individuals with smear-negative PTB microbiologically confirmed by: (i) CBNAAT was 0.695 ng/ml and (ii) culture was 0.615 ng/ml.</p><p><strong>Interpretation conclusions: </strong>The findings of this study suggest that individuals with smear-negative PTB and a urinary LAM value of >0.615 ng/ml were most likely to have microbiological confirmed TB while those with a LAM value <0.615 ng/ml >0.478 ng/ml are less likely and those with a value <0.478 ng/ml are unlikely to have microbiological confirmed TB.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographic information system-aided evaluation of epidemiological trends of dengue serotypes in West Bengal, India. 地理信息系统辅助评估印度西孟加拉邦登革热血清型的流行趋势。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_1055_23
Upasana Baskey, Priya Verma, Palash Mondal, Supradip Dutta, Aritra Biswas, Sagnik Bakshi, Raina Das, Sudipta Bhaduri, Dipankar Maji, Shanta Dutta, Provash Chandra Sadhukhan

Background objectives: West Bengal is a dengue-endemic State in India, with all four dengue serotypes in co-circulation. The present study was conceived to determine the changing trends of circulating dengue virus (DENV) serotypes in five consecutive years (2015-2019) using a geographic information system (GIS) during the dengue season in West Bengal, India.

Methods: Molecular serotyping of dengue NS1 sero-reactive serum samples from individuals with ≤5 days of fever was performed using conventional nested reverse transcriptase-PCR. GIS techniques such as Getis-Ord Gi* hotspot analysis and heatmap were used to elucidate dengue transmission based on the received NS1-positive cases and vector data analysis was used to point out risk-prone areas.

Results: A total of 3915 dengue NS1 sero-positive samples were processed from most parts of West Bengal and among these, 3249 showed RNA positivity. The major circulating serotypes were DENV 3 (63.54%) in 2015, DENV 1 (52.79%) in 2016 and DENV 2 (73.47, 76.04 and 47.15%) in 2017, 2018 and 2019, respectively. Based on the NS1 positivity, dengue infections were higher in males than females and young adults of 21-30 yr were mostly infected. Getis-Ord Gi* hotspot cluster analysis and heatmap indicate that Kolkata has become a hotspot for dengue outbreaks and serotype plotting on maps confirms a changing trend of predominant serotypes during 2015-2019 in West Bengal.

Interpretation conclusions: Co-circulation of all the four dengue serotypes was observed in this study, but only one serotype became prevalent during an outbreak. Representation of NS1-positive cases and serotype distribution in GIS mapping clearly showed serotypic shift in co-circulation. The findings of this study suggest the need for stringent surveillance in dengue-endemic areas to limit the impact of dengue and implement better vector-control strategies.

背景目标:西孟加拉邦是印度的登革热流行邦,所有四种登革热血清型共同流行。本研究旨在利用地理信息系统(GIS)确定印度西孟加拉邦登革热流行季节登革热病毒(DENV)血清型连续五年(2015-2019 年)的变化趋势:使用传统的巢式反转录酶-PCR技术对发热≤5天的登革热患者的登革热NS1血清反应样本进行分子血清分型。利用Getis-Ord Gi*热点分析和热图等地理信息系统技术,根据接收到的NS1阳性病例阐明登革热传播情况,并利用病媒数据分析指出高危地区:结果:西孟加拉邦大部分地区共处理了 3915 份登革热 NS1 血清阳性样本,其中 3249 份显示 RNA 阳性。主要的流行血清型分别为:2015 年 DENV 3(63.54%),2016 年 DENV 1(52.79%),2017 年、2018 年和 2019 年 DENV 2(73.47%、76.04% 和 47.15%)。根据NS1阳性率,登革热感染男性高于女性,21-30岁的青壮年感染者居多。Getis-Ord Gi*热点聚类分析和热图显示,加尔各答已成为登革热爆发的热点地区,地图上的血清型绘制证实了2015-2019年间西孟加拉邦主要血清型的变化趋势:本研究观察到所有四种登革热血清型的共同流行,但只有一种血清型在疫情爆发期间流行。在 GIS 地图中,NS1 阳性病例和血清型分布清楚地显示了共同流行中的血清型转变。这项研究的结果表明,有必要在登革热流行地区进行严格监测,以限制登革热的影响,并实施更好的病媒控制策略。
{"title":"Geographic information system-aided evaluation of epidemiological trends of dengue serotypes in West Bengal, India.","authors":"Upasana Baskey, Priya Verma, Palash Mondal, Supradip Dutta, Aritra Biswas, Sagnik Bakshi, Raina Das, Sudipta Bhaduri, Dipankar Maji, Shanta Dutta, Provash Chandra Sadhukhan","doi":"10.4103/ijmr.ijmr_1055_23","DOIUrl":"https://doi.org/10.4103/ijmr.ijmr_1055_23","url":null,"abstract":"<p><strong>Background objectives: </strong>West Bengal is a dengue-endemic State in India, with all four dengue serotypes in co-circulation. The present study was conceived to determine the changing trends of circulating dengue virus (DENV) serotypes in five consecutive years (2015-2019) using a geographic information system (GIS) during the dengue season in West Bengal, India.</p><p><strong>Methods: </strong>Molecular serotyping of dengue NS1 sero-reactive serum samples from individuals with ≤5 days of fever was performed using conventional nested reverse transcriptase-PCR. GIS techniques such as Getis-Ord Gi* hotspot analysis and heatmap were used to elucidate dengue transmission based on the received NS1-positive cases and vector data analysis was used to point out risk-prone areas.</p><p><strong>Results: </strong>A total of 3915 dengue NS1 sero-positive samples were processed from most parts of West Bengal and among these, 3249 showed RNA positivity. The major circulating serotypes were DENV 3 (63.54%) in 2015, DENV 1 (52.79%) in 2016 and DENV 2 (73.47, 76.04 and 47.15%) in 2017, 2018 and 2019, respectively. Based on the NS1 positivity, dengue infections were higher in males than females and young adults of 21-30 yr were mostly infected. Getis-Ord Gi* hotspot cluster analysis and heatmap indicate that Kolkata has become a hotspot for dengue outbreaks and serotype plotting on maps confirms a changing trend of predominant serotypes during 2015-2019 in West Bengal.</p><p><strong>Interpretation conclusions: </strong>Co-circulation of all the four dengue serotypes was observed in this study, but only one serotype became prevalent during an outbreak. Representation of NS1-positive cases and serotype distribution in GIS mapping clearly showed serotypic shift in co-circulation. The findings of this study suggest the need for stringent surveillance in dengue-endemic areas to limit the impact of dengue and implement better vector-control strategies.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140848514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic diversity of Mycobacterium leprae: Need to move towards genome-wide approaches. 麻风分枝杆菌的遗传多样性:需要转向全基因组方法。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_2383_22
Purna Dwivedi, Mukul Sharma, Afzal Ansari, Pushpendra Singh

Abstract: Leprosy, an ancient disease, continues to be a public health concern as it remains endemic in several countries. After reaching the elimination target (1/10,000) as a public health problem in 2005 in India, around 1.2 lakh cases have been detected every year over the last decade indicating active transmission of leprosy bacillus (Mycobacterium leprae). Single-nucleotide polymorphisms (SNPs), genomic insertions/deletions and variable-number tandem repeats (VNTRs) have been identified as genetic markers for tracking M. leprae transmission. As the leprosy bacilli cannot be cultured in vitro, molecular testing of M. leprae genotypes is done by polymerase chain reaction-based sequencing which provides a practical alternative for the identification of strains as well as drug resistance-associated mutations. Whole-genome sequencing (WGS) of M. leprae directly from clinical samples has also proven to be an effective tool for identifying genetic variations which can further help refine the molecular epidemiological schemes based on SNPs and VNTRs. However, the WGS data of M. leprae strains from India are scarce, being responsible for a gross under-representation of the genetic diversity of M. leprae strains present in India and need to be addressed suitably. Molecular studies of leprosy can provide better insight into phylogeographic markers to monitor the transmission dynamics and emergence of antimicrobial resistance. An improved understanding of M. leprae transmission is essential to guide efficient leprosy control strategies. Therefore, this review compiles and discusses the current status of molecular epidemiology, genotyping and the potential of genome-wide analysis of M. leprae strains in the Indian context.

摘要:麻风病是一种古老的疾病,在一些国家仍然流行,因此仍然是一个公共卫生问题。印度于 2005 年实现了消除麻风病这一公共卫生问题的目标(1/10,000),但在过去十年中,每年发现的麻风病例约为 120 万例,表明麻风杆菌(麻风分枝杆菌)的传播十分活跃。单核苷酸多态性(SNPs)、基因组插入/缺失和变数串联重复序列(VNTRs)已被确定为追踪麻风杆菌传播的遗传标记。由于麻风杆菌无法在体外培养,麻风杆菌基因型的分子检测是通过聚合酶链反应测序完成的,这为鉴定菌株和耐药性相关突变提供了一种实用的替代方法。直接从临床样本中对麻风杆菌进行全基因组测序(WGS)也被证明是鉴定基因变异的有效工具,有助于进一步完善基于 SNP 和 VNTR 的分子流行病学方案。然而,印度麻风杆菌菌株的 WGS 数据很少,导致印度麻风杆菌菌株的遗传多样性代表性严重不足,需要适当解决。麻风病的分子研究可以更好地了解系统地理标记,从而监测传播动态和抗菌药耐药性的出现。加深对麻风杆菌传播的了解对于指导有效的麻风病控制策略至关重要。因此,本综述汇编并讨论了印度麻风杆菌菌株的分子流行病学、基因分型和全基因组分析潜力的现状。
{"title":"Genetic diversity of Mycobacterium leprae: Need to move towards genome-wide approaches.","authors":"Purna Dwivedi, Mukul Sharma, Afzal Ansari, Pushpendra Singh","doi":"10.4103/ijmr.ijmr_2383_22","DOIUrl":"10.4103/ijmr.ijmr_2383_22","url":null,"abstract":"<p><strong>Abstract: </strong>Leprosy, an ancient disease, continues to be a public health concern as it remains endemic in several countries. After reaching the elimination target (1/10,000) as a public health problem in 2005 in India, around 1.2 lakh cases have been detected every year over the last decade indicating active transmission of leprosy bacillus (Mycobacterium leprae). Single-nucleotide polymorphisms (SNPs), genomic insertions/deletions and variable-number tandem repeats (VNTRs) have been identified as genetic markers for tracking M. leprae transmission. As the leprosy bacilli cannot be cultured in vitro, molecular testing of M. leprae genotypes is done by polymerase chain reaction-based sequencing which provides a practical alternative for the identification of strains as well as drug resistance-associated mutations. Whole-genome sequencing (WGS) of M. leprae directly from clinical samples has also proven to be an effective tool for identifying genetic variations which can further help refine the molecular epidemiological schemes based on SNPs and VNTRs. However, the WGS data of M. leprae strains from India are scarce, being responsible for a gross under-representation of the genetic diversity of M. leprae strains present in India and need to be addressed suitably. Molecular studies of leprosy can provide better insight into phylogeographic markers to monitor the transmission dynamics and emergence of antimicrobial resistance. An improved understanding of M. leprae transmission is essential to guide efficient leprosy control strategies. Therefore, this review compiles and discusses the current status of molecular epidemiology, genotyping and the potential of genome-wide analysis of M. leprae strains in the Indian context.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140855046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study. PET 时代晚期霍奇金淋巴瘤联合疗法的长期临床疗效:回顾性研究。
IF 4.2 4区 医学 Q1 Medicine Pub Date : 2024-02-01 Epub Date: 2024-04-04 DOI: 10.4103/ijmr.ijmr_3459_21
Swati Chugh, Goutam Panda, Smruti Mokal, Hasmukh Jain, Bhausaheb Bagal, Nehal Khanna, Sridhar Epari, Sachin Punatar, Lingaraj Nayak, Anant Gokarn, Naveen Khattry, Manju Sengar, Siddhartha Laskar, Jayant S Goda

Background objectives: The role of consolidation radiation therapy (CRT) after complete metabolic response to chemotherapy in advanced-stage (stage III and IV) Hodgkin lymphoma (HL) is controversial. This study was undertaken to assess the clinical outcomes in terms of event free survival, local failure free survival and overall survival in individuals with advanced HL treated with chemotherapy and CRT.

Methods: A retrospective review was conducted to study the long-term clinical outcomes in individuals diagnosed with HL and treated with chemotherapy and CRT from 2012 to 2016 at a tertiary cancer care hospital in India.

Results: Data from 203 study participants with advanced-stage HL were analyzed. Positron emission tomography-computed tomography (PET-CT) was done at baseline and after 2 cycles for response assessment. The median age at presentation was 32 yr [interquartile range (IQR): 26-46]. Early metabolic response (after 2 cycles) and delayed metabolic response (after 4 or 6 cycles) were observed in 74.4 and 25.6 per cent of individuals, respectively. With a median follow up of 52 months (IQR: 40-67), the five-year event-free survival (EFS), local failure-free survival (LFFS) and overall survival (OS) were 83.2, 95.1 and 94.6 per cent, respectively. On univariate analysis, extranodal disease was associated with inferior EFS (P=0.043). Haemoglobin <10.5 g/dl (P=0.002) and Hasenclever index >3 (P=0.00047) were associated with poorer OS. Relapses were observed in 28/203 (13.8%) study participants with predominance at central nodal stations. The median time to relapse was 19.4 months (IQR: 13-33). Local relapse alone (at the irradiated site) was observed in 5/28 study participants, systemic (distant) relapse in 14/28 individuals, while both systemic and local relapse was observed in 9/28 participants. Extranodal disease (P=0.05), bulky disease (P=0.005) and haemoglobin concentration ≤10.5 g/dl (P=0.036) were significant predictors for disease relapse.

Interpretation conclusions: Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.

背景目标:晚期(Ⅲ期和Ⅳ期)霍奇金淋巴瘤(HL)患者对化疗产生完全代谢反应后,巩固放疗(CRT)的作用存在争议。本研究旨在评估接受化疗和 CRT 治疗的晚期霍奇金淋巴瘤患者在无事件生存期、无局部失败生存期和总生存期方面的临床结果:方法:对印度一家三级癌症治疗医院2012年至2016年期间确诊为HL并接受化疗和CRT治疗的患者的长期临床结果进行回顾性研究:对203名晚期HL患者的数据进行了分析。在基线和两个周期后进行正电子发射断层扫描(PET-CT),以评估反应。发病时的中位年龄为 32 岁[四分位距(IQR):26-46]。分别有 74.4% 和 25.6% 的患者观察到了早期代谢反应(2 个周期后)和延迟代谢反应(4 或 6 个周期后)。中位随访时间为 52 个月(IQR:40-67),五年无事件生存率(EFS)、局部无失败生存率(LFFS)和总生存率(OS)分别为 83.2%、95.1% 和 94.6%。单变量分析显示,结节外疾病与较差的 EFS 相关(P=0.043)。血红蛋白3(P=0.00047)与较差的OS有关。28/203(13.8%)名研究参与者出现复发,主要集中在中央结节站。复发的中位时间为 19.4 个月(IQR:13-33)。5/28的研究参与者仅出现局部复发(在照射部位),14/28的参与者出现全身(远处)复发,9/28的参与者同时出现全身和局部复发。结节外疾病(P=0.05)、大块疾病(P=0.005)和血红蛋白浓度≤10.5 g/dl(P=0.036)是疾病复发的重要预测因素:晚期HL患者接受以蒽环类药物为基础的化疗(以多柔比星、博来霉素、长春新碱和达卡巴嗪为基础的蒽环类药物化疗方案)和CRT治疗后,长期预后良好。由于孤立的内场失败并不常见,因此选择性地对高危部位进行适形 RT 巩固治疗可改善最终的疾病预后。
{"title":"Long-term clinical outcomes of combined modality therapy for advanced-stage Hodgkin lymphoma in the PET era: A retrospective study.","authors":"Swati Chugh, Goutam Panda, Smruti Mokal, Hasmukh Jain, Bhausaheb Bagal, Nehal Khanna, Sridhar Epari, Sachin Punatar, Lingaraj Nayak, Anant Gokarn, Naveen Khattry, Manju Sengar, Siddhartha Laskar, Jayant S Goda","doi":"10.4103/ijmr.ijmr_3459_21","DOIUrl":"https://doi.org/10.4103/ijmr.ijmr_3459_21","url":null,"abstract":"<p><strong>Background objectives: </strong>The role of consolidation radiation therapy (CRT) after complete metabolic response to chemotherapy in advanced-stage (stage III and IV) Hodgkin lymphoma (HL) is controversial. This study was undertaken to assess the clinical outcomes in terms of event free survival, local failure free survival and overall survival in individuals with advanced HL treated with chemotherapy and CRT.</p><p><strong>Methods: </strong>A retrospective review was conducted to study the long-term clinical outcomes in individuals diagnosed with HL and treated with chemotherapy and CRT from 2012 to 2016 at a tertiary cancer care hospital in India.</p><p><strong>Results: </strong>Data from 203 study participants with advanced-stage HL were analyzed. Positron emission tomography-computed tomography (PET-CT) was done at baseline and after 2 cycles for response assessment. The median age at presentation was 32 yr [interquartile range (IQR): 26-46]. Early metabolic response (after 2 cycles) and delayed metabolic response (after 4 or 6 cycles) were observed in 74.4 and 25.6 per cent of individuals, respectively. With a median follow up of 52 months (IQR: 40-67), the five-year event-free survival (EFS), local failure-free survival (LFFS) and overall survival (OS) were 83.2, 95.1 and 94.6 per cent, respectively. On univariate analysis, extranodal disease was associated with inferior EFS (P=0.043). Haemoglobin <10.5 g/dl (P=0.002) and Hasenclever index >3 (P=0.00047) were associated with poorer OS. Relapses were observed in 28/203 (13.8%) study participants with predominance at central nodal stations. The median time to relapse was 19.4 months (IQR: 13-33). Local relapse alone (at the irradiated site) was observed in 5/28 study participants, systemic (distant) relapse in 14/28 individuals, while both systemic and local relapse was observed in 9/28 participants. Extranodal disease (P=0.05), bulky disease (P=0.005) and haemoglobin concentration ≤10.5 g/dl (P=0.036) were significant predictors for disease relapse.</p><p><strong>Interpretation conclusions: </strong>Individuals with advanced-stage HL treated with anthracycline-based chemotherapy (anthracycline-based chemotherapy with doxorubicin, bleomycin, vinblastine and dacarbazine regimen) and CRT had excellent long-term outcomes. As isolated infield failures are uncommon, selective consolidation with conformal RT to high-risk sites improves final disease outcomes.</p>","PeriodicalId":13349,"journal":{"name":"Indian Journal of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11050758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140859449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Indian Journal of Medical Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1